Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
© 2022. The Author(s)..
Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as a homologous two-dose regimen (Days 0 and 28). Here, we evaluate the safety (primary objective) and immunogenicity (secondary and exploratory objectives: magnitude and characterization of vaccine-induced humoral responses) of a third vaccination with MVA-MERS-S in a subgroup of trial participants one year after primary immunization. MVA-MERS-S booster vaccination is safe and well-tolerated. Both binding and neutralizing anti-MERS-CoV antibody titers increase substantially in all participants and exceed maximum titers observed after primary immunization more than 10-fold. We identify four immunogenic IgG epitopes, located in the receptor-binding domain (RBD, n = 1) and the S2 subunit (n = 3) of MERS-CoV-S. The level of baseline anti-human coronavirus antibody titers does not impact the generation of anti-MERS-CoV antibody responses. Our data support the rationale of a booster vaccination with MVA-MERS-S and encourage further investigation in larger trials. Trial registration: Clinicaltrials.gov NCT03615911.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Nature communications - 13(2022), 1 vom: 19. Juli, Seite 4182 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fathi, Anahita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 21.07.2022 Date Revised 17.08.2022 published: Electronic ClinicalTrials.gov: NCT03615911 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-022-31557-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343739690 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343739690 | ||
| 003 | DE-627 | ||
| 005 | 20231226021143.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-022-31557-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343739690 | ||
| 035 | |a (NLM)35853863 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fathi, Anahita |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2022 | ||
| 500 | |a Date Revised 17.08.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03615911 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Vaccine development is essential for pandemic preparedness. We previously conducted a Phase 1 clinical trial of the vector vaccine candidate MVA-MERS-S against the Middle East respiratory syndrome coronavirus (MERS-CoV), expressing its full spike glycoprotein (MERS-CoV-S), as a homologous two-dose regimen (Days 0 and 28). Here, we evaluate the safety (primary objective) and immunogenicity (secondary and exploratory objectives: magnitude and characterization of vaccine-induced humoral responses) of a third vaccination with MVA-MERS-S in a subgroup of trial participants one year after primary immunization. MVA-MERS-S booster vaccination is safe and well-tolerated. Both binding and neutralizing anti-MERS-CoV antibody titers increase substantially in all participants and exceed maximum titers observed after primary immunization more than 10-fold. We identify four immunogenic IgG epitopes, located in the receptor-binding domain (RBD, n = 1) and the S2 subunit (n = 3) of MERS-CoV-S. The level of baseline anti-human coronavirus antibody titers does not impact the generation of anti-MERS-CoV antibody responses. Our data support the rationale of a booster vaccination with MVA-MERS-S and encourage further investigation in larger trials. Trial registration: Clinicaltrials.gov NCT03615911 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Dahlke, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Krähling, Verena |e verfasserin |4 aut | |
| 700 | 1 | |a Kupke, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Okba, Nisreen M A |e verfasserin |4 aut | |
| 700 | 1 | |a Raadsen, Matthijs P |e verfasserin |4 aut | |
| 700 | 1 | |a Heidepriem, Jasmin |e verfasserin |4 aut | |
| 700 | 1 | |a Müller, Marcel A |e verfasserin |4 aut | |
| 700 | 1 | |a Paris, Grigori |e verfasserin |4 aut | |
| 700 | 1 | |a Lassen, Susan |e verfasserin |4 aut | |
| 700 | 1 | |a Klüver, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Volz, Asisa |e verfasserin |4 aut | |
| 700 | 1 | |a Koch, Till |e verfasserin |4 aut | |
| 700 | 1 | |a Ly, My L |e verfasserin |4 aut | |
| 700 | 1 | |a Friedrich, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Fux, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Tscherne, Alina |e verfasserin |4 aut | |
| 700 | 1 | |a Kalodimou, Georgia |e verfasserin |4 aut | |
| 700 | 1 | |a Schmiedel, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Corman, Victor M |e verfasserin |4 aut | |
| 700 | 1 | |a Hesterkamp, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Drosten, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Loeffler, Felix F |e verfasserin |4 aut | |
| 700 | 1 | |a Haagmans, Bart L |e verfasserin |4 aut | |
| 700 | 1 | |a Sutter, Gerd |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Addo, Marylyn M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 13(2022), 1 vom: 19. Juli, Seite 4182 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:1 |g day:19 |g month:07 |g pages:4182 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-022-31557-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 1 |b 19 |c 07 |h 4182 | ||